EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY-NC 4.0

Good engraftment after reduced intensity targeted busulfan‐based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies

Maximilian Klink, Matthias Felber, Ulrike Zeilhofer, Mathias Hauri-Hohl, Markus Schmugge, Daniel Drozdov iD, Tayfun Güngör iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30988 ↗

At a glance

Beobachtungsstudie in Pediatric Blood & Cancer, 2024. Written by Maximilian Klink and 6 co-authors. Institution: Medical Faculty, University of Zürich, Zürich, Switzerland. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Anemia, Sickle Cell, beta-Thalassemia. Cited 4 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Universitat Zurich.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Hematopoietic cell transplantation (HCT) is an established curative therapy for transfusion‐dependent thalassemia (TDT) and sickle cell disease (SCD). The latest American Society of Hematology guidelines recommend myeloablative preparative regimen in patients under 18 years of age. Procedure The objective was to demonstrate safety and efficacy of a reduced intensity conditioning (RIC) regimen including high‐dose fludarabine, anti‐thymocyte globulin, and targeted busulfan as a single alkylator to sub‐myeloablative exposures.

Results

Between 2012 and 2021, 11 patients with SCD and five patients with TDT and matched related donor (MRD) HCT were included. The median age at transplantation was 8.3 years (range: 3.7–18.8 years). The median administered busulfan AUC was 67.4 mg/L×h (range: 60.7–80 mg/L×h). Overall survival was 93.8% and event‐free survival 87.5% with one engrafted SCD patient with pre‐existing moyamoya disease succumbing after drainage of a subdural hematoma. One SCD patient developed a secondary graft failure and was treated with a second HCT. Myeloid chimerism was full in all other patients with a median follow‐up time of 4.1 years (range: 2.0–11.1 years), whereas T‐cell donor chimerism was frequently mixed.

Conclusion

This RIC conditioning followed by MRD HCT is sufficiently myeloablative to cure pediatric patients with hemoglobinopathies without the need for additional total body irradiation or thiotepa.

Subjects

MeSH terms (MEDLINE)

Hematopoietic Stem Cell TransplantationTransplantation ConditioningAnemia, Sickle Cellbeta-ThalassemiaHumansAntilymphocyte SerumBusulfanImmunosuppressive AgentsMaleFemaleChild, PreschoolChildAdolescentRetrospective StudiesCohort StudiesSwitzerlandVidarabine

Author keywords

hematologyhemoglobinopathiesnonmalignantstem cell transplantation

Substances

Antilymphocyte SerumBusulfanImmunosuppressive AgentsfludarabineVidarabine

Authors and institutions

  • Medical Faculty, University of Zürich, Zürich, Switzerland.
  • Division of Stem Cell Transplantation and Children's Research Center, University Children's Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Division of Hematology and Children's Research Center, University Children's Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kantonsspital Aarau, Aarau, Switzerland.

ORCID profiles: Daniel Drozdov, Tayfun Güngör

Funding

  • Universitat Zurich

Cite

APA

Klink, M., Felber, M., Zeilhofer, U., Hauri-Hohl, M., Schmugge, M., Drozdov, D., & Güngör, T. (2024). Good engraftment after reduced intensity targeted busulfan‐based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30988

Vancouver

Klink M, Felber M, Zeilhofer U, Hauri-Hohl M, Schmugge M, Drozdov D, et al. Good engraftment after reduced intensity targeted busulfan‐based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30988

BibTeX
@article{Klink2024,
  author = {Klink, Maximilian and Felber, Matthias and Zeilhofer, Ulrike and Hauri-Hohl, Mathias and Schmugge, Markus and Drozdov, Daniel and Güngör, Tayfun},
  title = {Good engraftment after reduced intensity targeted busulfan‐based conditioning and matched related donor hematopoietic cell transplantation in hemoglobinopathies},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30988}
}
Start for free →